Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-22-033332
Filing Date
2022-03-14
Accepted
2022-03-14 16:19:08
Documents
1
Period of Report
2022-03-14

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm228937-1_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm228937-1_3seq1.xml 3 2184
  Complete submission text file 0001104659-22-033332.txt   3901
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Issuer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O STEMLINE THERAPEUTICS, INC. 750 LEXINGTON AVENUE, 11TH FLOOR NEW YORK NY 10022
Business Address
Francomano Robert (Reporting) CIK: 0001797467 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33958 | Film No.: 22736876